Healthcare / BiotechnologyNasdaqCM
$1.88
-0.01 (-0.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.8M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$93M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-123.5%
↓Gross Margin
N/A
•Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
-1.9%
FCF CAGR
—
FCF margin
-3830.0%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $400000.0 · net income $-18.4M · FCF $-15.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $400000.00 | $400000.00 | $225000.00 | — | $1.9M | $2.4M | $1.6M | $2.0M | $444000.00 | $394000.00 | $948000.00 | $1.9M | $205000.00 | $1.0M | $1.3M | $520080.00 |
| Net Income | $-18.4M | $-18.4M | $-24.9M | $-65.0M | $-50.4M | $-23.2M | $-16.4M | $-17.6M | $-16.1M | $-14.5M | $-9.8M | $-6.6M | $-3.7M | $-6.2M | $-5.7M | $-12.1M |
| EBITDA | $-17.0M | $-17.0M | $-14.0M | $-27.8M | $-25.7M | — | — | $-15.6M | — | — | — | — | — | — | $-9.0M | $-9.3M |
| EPS | -1.75 | -1.75 | -6.50 | -106.19 | -115.60 | -60.00 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | 115.0% | 38.3% | 57.1% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -4650.5% | -4650.5% | -7392.9% | — | -1576.3% | -1312.1% | -854.9% | -782.4% | -3204.3% | -3622.8% | -1043.6% | -360.1% | -1873.2% | -662.1% | -730.4% | -1856.3% |
| Net Margin | -4594.3% | -4594.3% | -11069.8% | — | -2674.7% | -978.8% | -1003.6% | -871.8% | -3627.3% | -3688.3% | -1030.0% | -357.9% | -1788.3% | -615.5% | -444.5% | -2334.7% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.24 | 0.24 | 0.21 | 1.11 | 0.41 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 11.88 | 11.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-15.3M | $-15.3M | $-18.8M | $-36.2M | $-49.1M | $-35.0M | $-14.4M | $-14.9M | $-14.4M | $-14.5M | — | — | — | $-4.9M | $-6.0M | $-5.3M |
| Returns | ||||||||||||||||
| ROE | -123.5% | -123.5% | -116.8% | -422.7% | -79.4% | -21.4% | -29.0% | -714.3% | -99.6% | -163.0% | -98.3% | -59.0% | -60.1% | -122.3% | -92.0% | -6195.1% |
| Valuation | ||||||||||||||||
| P/B | 1.32 | 1.32 | 0.34 | 0.49 | 0.89 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 77.8% | 77.8% | — | — | — | 44.7% | -18.8% | 354.5% | 12.7% | -58.4% | -48.8% | 802.9% | -79.6% | -21.1% | 145.5% | — |
| EPS Growth | 73.1% | 73.1% | 93.9% | 8.1% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+128.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.50 → -1.75
Residual
+128.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.